After this recent quarterly performance and the resultant increase in stock price, an important question arises: is DXCM ...

Oura announced the rollout of two new features, Meals and Glucose, to give users a clearer view of how daily behaviors affect ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at ...

DexCom's growth trend improved in 1Q25, but competition and shrinking market potential keep upside limited. Find out why DXCM ...

DexCom Inc. closed 38.36% below its 52-week high of $132.26, which the company reached on May 17th.

DexCom Inc. closed 39.31% below its 52-week high of $132.26, which the company reached on May 17th.

Ōura, maker of a health-monitoring smart ring, announced that it will use AI to track and analyze two new metabolic health features: meals and glucose.

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump’s tariffs are ...

DexCom, Inc. (NASDAQ: DXCM) has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) ...

Glucose tracking is a natural part of Oura’s $75 million investment from Dexcom.